Low-mass-ion discriminant equation: A new concept for colorectal cancer screening

International Journal of Cancer

Volumn 134, Issue 8, 2014, Pages 1844-1853

  Lee, Jun Hwa ^a   Kim, Kyung Hee ^a   Park, Ji Won ^a   Chang, Hee Jin ^a   Kim, Byung Chang ^a   Kim, Sun Young ^a   Kim, Kwang Gi ^a   Lee, Eun Sook ^a   Kim, Dae Yong ^a   Oh, Jae Hwan ^a   Yoo, Byong Chul ^a   Kim, In Hoo ^a  

^a National Cancer Center   (South Korea)

Author keywords

MALDI TOF mass spectrometry; pattern recognition; serum profiling

Indexed keywords

MALDI-TOF MASS SPECTROMETRY; PATTERN RECOGNITION; SERUM PROFILING;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84893750466     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28517     Document Type: Article

References (27)

1. Pollak MN, Foulkes WD,. Challenges to cancer control by screening. Nat Rev Cancer 2003; 3: 297-303. (Pubitemid 37328865)
2. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008; 58: 130-60. (Pubitemid 351830299)
3. Davies RJ, Miller R, Coleman N,. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer 2005; 5: 199-209. (Pubitemid 40314951)
4. Graser A, Stieber P, Nagel D, et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 2009; 58: 241-8.
5. Duffy MJ,. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 2001; 47: 624-30. (Pubitemid 32275803)
6. deVos T, Tetzner R, Model F, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 2009; 55: 1337-46.
7. Melotte V, Lentjes MH, van den Bosch SM, et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst 2009; 101: 916-27.
8. Haug U, Hundt S, Brenner H,. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. Br J Cancer 2008; 99: 133-5. (Pubitemid 351920225)
9. Sawyers CL,. The cancer biomarker problem. Nature 2008; 452: 548-52. (Pubitemid 351483368)
10. Chen T, Xie G, Wang X, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics 2001; 10: M110.004945.
11. Asiago VM, Alvarado LZ, Shanaiah N, et al. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res 2010; 70: 8309-18.
12. Yoo BC, Kong SY, Jang SG, et al. Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling. BMC Cancer 2010; 10: 55.
13. Kelly AD, Breitkopf SB, Yuan M, et al. Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC/MS/MS: application in sarcoma. PLoS One 2011; 6: e25357.
14. Nishiumi S, Kobayashi T, Ikeda A, et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One 2012; 7: e40459.
15. Chan EC, Koh PK, Mal M, et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res 2009; 8: 352-61.
16. Bligh EG, Dyer WJ,. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-7.
17. Iverson SJ, Lang SLC, Cooper MH,. Comparison of the Bligh and Dyer and Folch methods for total lipid determination in a broad range of marine tissue. Lipids 2001; 36: 1283-7. (Pubitemid 34007983)
18. Folch J, Lees M, Stanley GHS,. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497-509.
19. Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 638-58.
20. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006; 116: 271-84. (Pubitemid 43121812)
21. Okholm M, Iversen LH, Thorlacius-Ussing O, et al. Fibrin and fibrinogen degradation products in plasma of patients with colorectal adenocarcinoma. Dis Colon Rectum 1996; 39: 1102-6. (Pubitemid 26330518)
22. Davalos D, Akassoglou K,. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 2012; 34: 43-62.
23. Ingenbleek Y, Young V,. Transthyretin (prealbumin) in health and disease: nutritional implications. Annu Rev Nutr 1994; 14: 495-533. (Pubitemid 24261848)
24. Fentz AK, Spörl M, Spangenberg J, et al. Detection of colorectal adenoma and cancer based on transthyretin and C3a-desArg serum levels. Proteomics Clin Appl 2007; 1: 536-44.
25. Mazurek S, Boschek CB, Hugo F, et al. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005; 15: 300-8. (Pubitemid 41058775)
26. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-3. (Pubitemid 351380249)
27. Mazurek S, Grimm H, Boschek CB, et al. Pyruvate kinase type M2: a crossroad in the tumor metabolome. Br J Nutr 2002; 87: S23-S29. (Pubitemid 34134101)